Autologous IC-Nine, CD30 CAR, and Constitutive IL7R Expressing EBVST for CD30 Lymphoma (ANCILE-30) | MicrobiomeTrials← Back to trialsNCT07729397
Autologous IC-Nine, CD30 CAR, and Constitutive IL7R Expressing EBVST for CD30 Lymphoma (ANCILE-30)
RecruitingPHASE1INTERVENTIONAL
Trial Details
Start: 2027-01-15Est. Completion: 2030-03-31
Enrollment target: 21 participants Locations- Houston Methodist Hospital, Houston, Texas, United States
Other microbiome trials you might be interested in
B-cell Non-Hodgkin LymphomaDiffuse Large B Cell LymphomaFollicular LymphomaMantle Cell LymphomaB-cell Lymphoma
This first-in-human study will evaluate the recommended dose for further clinical development, safety, tolerability, ant…
Baltimore, United StatesEst. completion Sep 2027
Ann Arbor Stage II Diffuse Large B-Cell LymphomaAnn Arbor Stage III Diffuse Large B-Cell LymphomaAnn Arbor Stage IV Diffuse Large B-Cell Lymphoma
This randomized phase II trial studies how well rituximab and combination chemotherapy with or without lenalidomide work…
Anchorage, United StatesEst. completion Mar 26, 2020
Diffuse Large B-Cell Lymphoma (DLBCL)
A Single-Arm, Open-Label, Multicenter Phase II Trial of CRP Regimen (Chidamide, Rituximab, Polatuzumab Vedotin) in Treat…
Tianjin, ChinaEst. completion Jul 30, 2028